Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew R Conery

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|August 18, 2010
High-throughput screens in diploid cells identify factors that contribute to the acquisition of chromosomal instabilityAndrew R Conery, Ed Harlow
Proceedings of the National Academy of Sciences of the United States of America|August 18, 2010
Nucleoside diphosphate kinase Nm23-H1 regulates chromosomal stability by activating the GTPase dynamin during cytokinesisAndrew R Conery, Sanja Sever, Ed Harlow
Nature Chemical Biology|December 25, 2021
Small molecule targeting of chromatin writers in cancerAndrew R Conery, Jennifer L Rocnik, Patrick Trojer
Nature Reviews. Drug Discovery|July 6, 2019
Bromodomains: a new target class for drug developmentAndrea G Cochran, Andrew R Conery, Robert J Sims
Nature Cell Biology|April 24, 2004
Akt interacts directly with Smad3 to regulate the sensitivity to TGF-beta induced apoptosisAndrew R Conery, Yanna Cao, E Aubrey Thompson, et al.
Genes & Development|April 19, 2011
A kinase shRNA screen links LATS2 and the pRB tumor suppressorKatrin Tschöp, Andrew R Conery, Larisa Litovchick, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 28, 2011
Targeting MYC dependence in cancer by inhibiting BET bromodomainsJennifer A Mertz, Andrew R Conery, Barbara M Bryant, et al.
Plos One|March 30, 2022
CREBBP/EP300 acetyltransferase inhibition disrupts FOXA1-bound enhancers to inhibit the proliferation of ER+ breast cancer cellsArchana Bommi-Reddy, Sungmi Park-Chouinard, David N Mayhew, et al.
Cancer Research|January 14, 2016
Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic ResponseAndrew R Conery, Richard C Centore, Kerry L Spillane, et al.
Elife|January 6, 2016
Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myelomaAndrew R Conery, Richard C Centore, Adrianne Neiss, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Proceedings of the National Academy of Sciences of the United States of America|August 18, 2010
High-throughput screens in diploid cells identify factors that contribute to the acquisition of chromosomal instabilityAndrew R Conery, Ed Harlow
Proceedings of the National Academy of Sciences of the United States of America|August 18, 2010
Nucleoside diphosphate kinase Nm23-H1 regulates chromosomal stability by activating the GTPase dynamin during cytokinesisAndrew R Conery, Sanja Sever, Ed Harlow
Nature Chemical Biology|December 25, 2021
Small molecule targeting of chromatin writers in cancerAndrew R Conery, Jennifer L Rocnik, Patrick Trojer
Nature Reviews. Drug Discovery|July 6, 2019
Bromodomains: a new target class for drug developmentAndrea G Cochran, Andrew R Conery, Robert J Sims
Nature Cell Biology|April 24, 2004
Akt interacts directly with Smad3 to regulate the sensitivity to TGF-beta induced apoptosisAndrew R Conery, Yanna Cao, E Aubrey Thompson, et al.
Genes & Development|April 19, 2011
A kinase shRNA screen links LATS2 and the pRB tumor suppressorKatrin Tschöp, Andrew R Conery, Larisa Litovchick, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 28, 2011
Targeting MYC dependence in cancer by inhibiting BET bromodomainsJennifer A Mertz, Andrew R Conery, Barbara M Bryant, et al.
Plos One|March 30, 2022
CREBBP/EP300 acetyltransferase inhibition disrupts FOXA1-bound enhancers to inhibit the proliferation of ER+ breast cancer cellsArchana Bommi-Reddy, Sungmi Park-Chouinard, David N Mayhew, et al.
Cancer Research|January 14, 2016
Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic ResponseAndrew R Conery, Richard C Centore, Kerry L Spillane, et al.
Elife|January 6, 2016
Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myelomaAndrew R Conery, Richard C Centore, Adrianne Neiss, et al.
Pageof 2